The assessment of antimalarial drug efficacy in vivo.

Antimalarials / pharmacology Drug Resistance / genetics Humans Malaria / prevention & control Malaria, Falciparum / drug therapy Malaria, Vivax / drug therapy Parasitemia / drug therapy Plasmodium falciparum / genetics Plasmodium vivax / genetics
antimalarial drugs chemoprevention malaria pharmacometric antimalarial resistance monitoring (PARM) pharmacometrics treatment

Journal

Trends in parasitology
ISSN: 1471-5007
Titre abrégé: Trends Parasitol
Pays: England
ID NLM: 100966034

Informations de publication

Date de publication:
08 2022
Historique:
received: 12 03 2022
revised: 13 05 2022
accepted: 16 05 2022
pubmed: 10 6 2022
medline: 19 7 2022
entrez: 9 6 2022
Statut: ppublish

Résumé

Currently recommended methods of assessing the efficacy of uncomplicated falciparum malaria treatment work less well in high-transmission than in low-transmission settings. There is also uncertainty how to assess intermittent preventive therapies and seasonal malaria chemoprevention (SMC), and Plasmodium vivax radical cure. A pharmacometric antimalarial resistance monitoring (PARM) approach is proposed specifically for evaluating slowly eliminated antimalarial drugs in areas of high transmission. In PARM antimalarial drug concentrations at recurrent parasitaemia are measured to identify outliers (i.e., recurrent parasitaemias in the presence of normally suppressive drug concentrations) and to evaluate changes over time. PARM requires characterization of pharmacometric profiles but should be simpler and more sensitive than current molecular genotyping-based methodologies. PARM does not require parasite genotyping and can be applied to the assessment of both prevention and treatment.

Identifiants

DOI: 10.1016/j.pt.2022.05.008 PMID: 35680541 PMC: PMC7613059
pubmed: 35680541
pii: S1471-4922(22)00111-8
doi: 10.1016/j.pt.2022.05.008
pmc: PMC7613059
mid: EMS145861
pii:
doi:

Substances chimiques

Antimalarials 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

660-672

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 033417
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 093956
Pays : United Kingdom

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The author declares no competing interests.

Références

Nat Commun. 2019 Dec 6;10(1):5595
pubmed: 31811128
Malar J. 2014 Dec 09;13:483
pubmed: 25486998
Trans R Soc Trop Med Hyg. 1947 May;40(5):621-76
pubmed: 20243883
Lancet. 2010 Nov 13;376(9753):1647-57
pubmed: 21062666
Am J Trop Med Hyg. 2003 Nov;69(5):558-63
pubmed: 14695097
Malar J. 2015 Sep 22;14:359
pubmed: 26390866
Bioanalysis. 2010 Nov;2(11):1839-47
pubmed: 21083492
Clin Pharmacol Ther. 2020 May;107(5):1179-1188
pubmed: 31652336
Expert Opin Drug Saf. 2018 Nov;17(11):1129-1144
pubmed: 30351243
Antimicrob Agents Chemother. 2013 Dec;57(12):5792-807
pubmed: 24002099
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29661873
Lancet Infect Dis. 2018 Apr;18(4):e119-e132
pubmed: 29395997
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29463542
Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):207-11
pubmed: 9764335
J Infect Dis. 2010 Feb 15;201(4):570-9
pubmed: 20085495
Infect Dis Clin North Am. 2012 Sep;26(3):637-54
pubmed: 22963775
Malar J. 2008 Jan 11;7:9
pubmed: 18186948
Am J Trop Med Hyg. 1995 Nov;53(5):522-5
pubmed: 7485711
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30038039
Malar J. 2011 Oct 11;10:297
pubmed: 21989376
Malar J. 2021 Mar 21;20(1):161
pubmed: 33743731
Malar J. 2018 Jul 11;17(1):258
pubmed: 29996844
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):669-86
pubmed: 17620000
Malar J. 2009 Nov 11;8:253
pubmed: 19906307
J Clin Microbiol. 2014 Sep;52(9):3303-9
pubmed: 24989601
Lancet Infect Dis. 2018 Jun;18(6):627-639
pubmed: 29422384
Am J Trop Med Hyg. 2021 Mar 15;104(5):1820-1829
pubmed: 33724925
Trends Parasitol. 2008 Apr;24(4):159-63
pubmed: 18353727
Clin Pharmacol Ther. 2011 Feb;89(2):268-75
pubmed: 21191379
Lancet Infect Dis. 2017 Jan;17(1):e15-e20
pubmed: 27839929
Lancet Child Adolesc Health. 2020 Oct;4(10):775-789
pubmed: 32946831
Lancet. 2019 Sep 14;394(10202):929-938
pubmed: 31327563
J Infect Dis. 2019 Apr 16;219(9):1483-1489
pubmed: 30657916
N Engl J Med. 2019 Jan 17;380(3):229-241
pubmed: 30650326
Clin Microbiol Rev. 2011 Apr;24(2):377-410
pubmed: 21482730
Malar J. 2011 Nov 10;10:339
pubmed: 22074219
PLoS One. 2017 Jan 4;12(1):e0169307
pubmed: 28052109
Bull World Health Organ. 1987;65(3):357-61
pubmed: 3311438
Elife. 2021 Jul 06;10:
pubmed: 34225842
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Nat Commun. 2019 Jan 29;10(1):480
pubmed: 30696903
Trends Parasitol. 2002 Oct;18(10):458-64
pubmed: 12377597
Antimicrob Agents Chemother. 2011 May;55(5):1827-30
pubmed: 21383088
Antimicrob Agents Chemother. 2015 Jul;59(7):4260-71
pubmed: 25963981
Antimicrob Agents Chemother. 2004 Nov;48(11):4271-80
pubmed: 15504852

Auteurs

Nicholas J White (NJ)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK. Electronic address: nickw@tropmedres.ac.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiparasitaires › Antiprotozoaires › Antipaludiques › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Infection › Maladies vectorielles › Paludisme › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Infection › Maladies vectorielles › Paludisme › Paludisme à Plasmodium falciparum › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Infection › Maladies vectorielles › Paludisme › Paludisme à Plasmodium vivax › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Parasitémie › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Eucaryotes › Alveolata › Apicomplexa › Haemosporida › Plasmodium › Plasmodium falciparum › The assessment of antimalarial drug efficacy in vivo.
questionsmedicales.fr › Eucaryotes › Alveolata › Apicomplexa › Haemosporida › Plasmodium › Plasmodium vivax › The assessment of antimalarial drug efficacy in vivo.